Drug Pipeline

RP1 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
2
Recruiting
1
Phase 3
5
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-16 NCT06264180
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1…		 Trial sites expanded: 73 -> 81 locations
Active Studies by Phase
Phase 3
1
Phase 2
2
Phase 1/2
1
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06264180 VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1… Advanced Melanoma Recruiting
Phase 2
NCT03767348 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Non-Small Cell Lung Cancer (NSCLC) Active, Not Recruiting
NCT06898970 Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for… Angiosarcoma Active, Not Recruiting
Phase 1/2
NCT05858229 Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. Squamous Cell Carcinoma Active, Not Recruiting
Early Phase 1
NCT06216938 RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Melanoma Recruiting
Sponsors Running RP1 Trials
Replimune Inc. (1) Sherrif Ibrahim (1) Yana Najjar (1) Replimune, Inc. (1) Varun Monga, MBBS (1)
Disease Areas
Melanoma (3) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Sarcoma (1)
Get alerts when RP1 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free